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Toward universal protein post-translational
modification detection in high throughput
format†
Harri Ha¨rma¨, *a Natalia Tong-Ochoa, a Arjan J. van Adrichem, ‡c
Ilian Jelesarov, b Krister Wennerberg c and Kari Kopra a
Post-translational modification (PTM) of proteins plays essential
regulatory roles in a variety of pathological conditions. Reliable
and practical assays are required to accelerate the discovery of inhibitors
and activators for PTM related diseases. Today,methodologies are based
on specific or group-specific PTM recognition of e.g. phosphate for
kinase activity without extending to other type of PTMs. Here we have
established a universal time-resolved luminescence assay on a peptide-
break platform for the direct detection of wide variety of PTMs. The
developed assay is based on the leucine zipper concept wherein a
europium-chelate labeled detection peptide and a non-labeled peptide
substrate form a highly luminescent dimer. As an active PTM enzyme at
sub or low nanomolar concentrationmodifies the substrate peptide, the
luminescent signal of the detached detection peptide is quenched in the
presence of soluble quenchers. The functionality of this universal assay
technique has been demonstrated for the monitoring of phos-
phorylation, dephosphorylation, deacetylation, and citrullinationwith
high applicability also to other PTMs in a high throughput format.
Post-translational modifications (PTMs) play pivotal roles in
generating functional protein diversity for cellular function
regulation. PTMs can define new recognition patterns, enzyme
activities, localization and protein turnover controlling biolo-
gical processes and, therefore, also disease conditions.1 One of
the main challenges in studying protein PTMs on a large scale
for drug discovery applications is the development of universal
detection methods to investigate multiple diﬀerent PTMs with
a single platform. A variety of sensitive luminescence-based
systems are commercially available for specific PTMs. Tradi-
tional approaches rely on the use of specific antibodies using
detection techniques such as time-resolved luminescence reso-
nance energy transfer (TR-LRET).2–4 Universal assays for
enzyme activity have been developed using nucleotide detection
methods for a variety of enzymes depending on the product
being formed such as AMP for ligases, ADP for kinases, and
UDP for glycosyltransferases.5,6 However, these non-direct
approaches are limited to nucleotide-dependent enzymes and
secondary products are detected. Other group-specific assays for
kinases and phosphatases have been successfully developed but
these methods have been limited to a single type of post-
translational modification.7–9 Universal single-platform methods
enable cost-effective assays and rapid turn-over with minimal
method steps using fixed reagents when seeking novel drug
candidates from molecular libraries.
Herein, we report a universal peptide-break technology for
enzyme activity monitoring based on the leucine zipper peptides.
Leucine zippers are coiled-coil dimerization domains of the
basic-region leucine zipper (bZIP) transcription factor proteins
(Fig. 1a). Leucine zippers are typically formed from approx. 30
amino acids in heptad repeats denoted as (abcdefg)n with leu-
cines in d positions contributing strongly to the peptide-pair
interaction having KD values ranging from pM to high mM.
10,11
The universal peptide-break detection platform for PTMs was
constructed on our quenching resonance energy transfer (QRET)
detection technology.12–16 The QRET technique distinguishes
between the leucine zipper complex and the dissociated post-
translationally modified peptides in the presence of a soluble
quencher molecule (Fig. 1b). High binding peptide motifs
consisting of labeled peptide and enzyme substrate peptide
interact when the substrate peptide carry no PTMs. At peptide
pairing a high luminescence signal is measured as the europium-
chelate label is protected from the soluble quenchers. Using a
non-modified peptide, an active enzyme transfers a given
modification to the peptide substrate, the peptides dissociate
and a decreased luminescence signal is monitored. The peptide
pair re-associates when the PTM is cleaved from the target site
providing a method to investigate PTMs to both directions of
modification. The functionality of the concept was demonstrated
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with four different PTM enzyme groups: kinase, phosphatase,
deacetylase and amidinotransferase.
The initial work was based on the peptide design using
highly characterized leucine zipper from the Fos and Jun
proteins which form a heterodimeric complex referred to as
transcription factor AP-1.11 Jun and Fos sequences of 36 amino
acid length from the leucine zipper domain were selected to
serve as peptide substrate and detection peptide respectively. A
tyrosine phosphorylated Jun (p-Jun), non-phosphorylated Jun
and non-modified Fos were commercially synthesized. We first
investigated the helicity of the peptides using circular dichroism
(CD) at 30 mM peptide concentration. The CD spectrum showed
that the non-phosphorylated Jun/Fos pair formed a typical
helical structure while the helical structure was lost using the
phosphorylated p-Jun peptide (Fig. 2a). This corroborated that
the principle of the method was valid. A critical point in the
development was the redesign of the leucine zipper sequences
to achieve optimal peptide-pair binding with suﬃcient aﬃnity
and dissociation properties. Peptides with higher aﬃnity were
in demand to develop the concept to measure PTMs with higher
sensitivity by shifting the peptide break-down point to nano-
molar concentration. As an initial target we chose tyrosine
kinase EGFR, which has shown not to possess high sequence
specificity in vitro. Phosphorylated/non-phosphorylated tyrosine
peptides were synthesized for these initial experiments and this
provided a basis to investigate the concept without large
sequence and structural limitations for the binding tests and
subsequent enzymatic assay optimization. CD measurements
for phosphotyrosine (TyroP-LZ) or non-phosphotyrosine peptide
(Tyro-LZ) and EuLZ (non-labeled peptide for CD measurements)
peptide pairs indicated that both TyroP-LZ and Tyro-LZ form a
pair with the detection peptide at 30 mM concentration. The
(222 nm/208 nm) ratios for Tyro-LZ/TyroP-LZ with non-labeled
EuLZ were 0.75 and 0.77 respectively. The corresponding values
for Jun/p-Jun and Fos were 0.89 and 0.56, respectively. This
indicates substantial a-helicity for the modified Tyro-peptide
pairs and Jun/Fos pair (Fig. 2a and b). Thereafter, the low
aﬃnity Jun/p-Jun and high aﬃnity TyroP-LZ/Tyro-LZ peptides
were investigated using the labeled detection peptides (Fos and
EuLZ) in a homogeneous QRET binding assay. The substrate
peptides were titrated in the assay and tested against the
corresponding europium-labeled peptides at a fixed concentration
(Fig. 2c and d). The binding of Tyro-LZ/EuLZ shifted from low
nanomolar to high nanomolar binding of TyroP-LZ/EuLZ providing
an EC50 ratio of approximately 100 between the phosphorylated vs.
non-phosphorylated peptides (Fig. 2d). From this data one can
conclude that the binding of the phosphorylated peptide observed
at micromolar range also explains the peptide pairing at 30 mM
peptide concentration in the CD studies. The binding aﬃnity of the
Tyro-LZ/EuLZ pair was improved approximately 1000-fold compared
to the Jun/Fos peptides in the QRET assay (Fig. 2c), providing the
basis to measure PTMs at nanomolar level in a high throughput
screening format.
To demonstrate the functionality of the method we run
enzymatic phosphorylation assay for EGFR. The assay confirmed
the result obtained with the commercially phosphorylated TyroP-
peptide (Fig. 3a). Next, the universality of the method was
demonstrated using a variety of substrate sequences suitable
for diﬀerent enzymes (Table 1). Peptides were selected to contain
the consensus sequence and thus required specificity to each
enzymatic activity. With the designed peptide substrates we ran
dose–response measurements for selective and non-selective
inhibitors and an activator against PKA and EGFR kinases,
Fig. 1 Principle of the universal peptide-break technology and leucine
zipper interaction. (A) In the heptad-repeat leucine zipper complex structure
d-positions are occupied with leucines and typically a-positions with hydro-
phobic amino acids. Positions e and g contain typically charged residues
further contributing to the binding. (B) In the peptide-break technology, high
europium (Eu) luminescence is detected upon leucine zipper complex
formation and dimer detachment promotes luminescence quenching.
Fig. 2 Structural and binding studies of phosphorylated and non-phos-
phorylated LZ peptides. CD spectra of peptides with (A) Jun (black)/p-Jun
(red) with Fos and (B) Tyro-LZ (red)/TyroP-LZ (black) with non-labeled
EuLZ show no helicity for p-Jun/Fos pair compared to the remaining pairs. The
homogeneous QRET binding tests (C) for Jun (black)/p-Jun (red) with Eu-Fos
and (D) for Tyro-LZ (black)/TyroP-LZ (red) with EuLZ resulted in higher
nanomolar aﬃnity for Tyro-LZ/EuLZ peptides compared to Jun/Eu-Fos pairs.
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PTP1B phosphatase, Sirtuin1 and HDAC3 deacetylases and
PAD4 amidinotransferase for citrullination. The dose–response
curves were measured using 0.5–3 nM of enzyme and typically
10 nM of substrate and detection peptides in a total volume of
50 ml (Table S1, ESI†). The obtained IC50 values were compar-
able to the literature values and the assay signal-to-background
(S/B) ratios range between 4–97 (Table S2, ESI†). The data
provided suggests that the peptide-break detection platform
can be extrapolated to other PTMs regardless of the product
being formed using the single-label approach.
Typically, we measured the luminescence signal in an end-
point fashion but without reaction stopping agent. To enable
real-time kinetic monitoring of the enzyme activity the protocol
was modified so that ATP and kinase (EGFR and PKA) were
added to the wells at the end to initiate the reaction. The data
suggests that the method is highly applicable to continuous
signal reading to measure reaction kinetics (Fig. S1, ESI†). This
is in line with our previous QRET assay development where
kinetic measurements have been demonstrated.13,14
Assay performance parameters were further studied with
phosphorylation monitoring prior to a compound library screening.
Compound library stocks are generally stored in DMSO and assays
with high DMSO tolerance are prerequisite. Thus a varying
concentration of DMSO (0–10%) was tested in the PKA assay.
Despite the fact that luminescence signal levels increased
approximately 4-fold at the highest DMSO concentration,
compared to 0% DMSO concentration, the S/B remained
unchanged providing an equal assay performance at all tested
DMSO concentrations (Fig. S2, ESI†). The final assay validation
was performed by running a small-scale HTS screen with the
Published Kinase Inhibitor Set (PKIS) library. Prior to this, the
PKA and EGFR kinase assays were miniaturized to 10 ml for
the screening of 356 compounds at 1 mM concentration. We
found 10/13 known PKA inhibitors in the screen having IC50
values lower than 1 mM considering 3SD threshold (Fig. 4);
whereas in the EGFR assay screen, 42/48 known inhibitors were
found considering 6SD threshold (Fig. S3, ESI†). Higher threshold
value was chosen to the EGFR assay due to higher number of active
compounds in the library. Assay robustness was investigated
during the PKA screen and an average Z0 value of 0.67 was
obtained using 96 negative and positive controls (0 and 1 mM
staurosporine) measured from three plates each having Z0 value
of 0.68, 0.68 and 0.65. Low assay variation shows not only high
reliability and HTS compatibility but reduces also the need
for high reagent concentrations resulting in high sensitivity
(Fig. 4 and Fig. S3, ESI†).
We have successfully developed a detection method potentially
suitable for universal PTM detection. The key benefit of the
method utilizing the peptide-break technology is its versatility.
The method is based on the peptide pairing and dissociation as
the substrate peptide is modified with an active PTM enzyme.
Fig. 3 Dose–responsemeasurements for the target enzymes at 0.5–3.0 nM
concentration level: (A) EGFR and (B) PKA kinases, (C) PTP1B phosphatase,
(D) PAD4 amidinotransferase at varying CaCl2 concentrations, (E) HDAC3
and (F) SIRT1 deacetylases using specific and universal inhibitors and
an activator. Calculated IC50 values were comparable to the references
(Table S2, ESI†).
Table 1 PTM target enzymes and leucine zipper peptides. The working window is shown with EC50 ratios for commercially modified vs. non-modified
peptide binding
Peptide Enzyme target PTM Consensus sequence
EC50 ratio (modified/
non-modified peptide)
Tyro-LZ EGFR Phosphorylation –Y– 100
Ser-LZ PKA Phosphorylation –RRxS– n.d.
TyroP-LZ PTP1B Dephosphorylation –pY– 100
LysAc-LZ Sirt 1 Deacetylation –(Ac)KGA– 50
LysAc-LZ HDAC3 Deacetylation –(Ac)KGA– 50
Arg-LZ PAD4 Citrullination –R– n.d.
Fig. 4 Validation of the universal peptide-break technology using PKIS library
using PKA. (A) Screening was performed at 1 mM compound concentration
with 3SD threshold for PKA. The number of detected compounds are
comparable with the Nanosyn Caliper screening information in the
literature.17 (B) Average Z0 value of 0.67 was calculated for the PKA kinase
assay and the S/B ratio was 12.
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For the end-user, the assay development is simple as the
substrate peptide is solely modified to contain target-specific
sequence for enzyme while the detection peptide is kept the
same for all peptide pairs. The detection platform is potentially
applicable to diﬀerent PTMs irrespective of the product being
formed during the PTM enzymatic assay. Moreover, the HTS
compatible technique has high sensitivity and low cost due to
low enzyme concentration requirements and the single label
concept. Our data suggests that the methodology may provide an
inexpensive luminescence-based detection concept to high through-
put screening for multiple PTM targets using a single platform.
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